http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
http://findarticles.com/p/articles/mi_m0689/is_2_55/ai_n16084680/pg_4?tag=artBody;col1
For patients truly allergic to penicillin, the risk of a reaction from a cephalosporin with side chains that differ from penicillin/amoxicillin (cefuroxime, cefpodoxime, cefdinir, and ceftriaxone, as endorsed by the AAFP) is so low that use is justified and medico-legally defensible by the currently available evidence...
Penicillin-allergic patients have indeed shown an increased incidence of allergic reactions to cephalothin, cephaloridine, cephalexin, cefadroxil, cefazolin, and cefamandole. However, the risk has been overestimated because most studies reporting this cross-reactivity were flawed (because penicillins were contaminated with cephalosporins) and then failed to account for the fact that penicillin-allergic patients have a 3-fold increased risk of allergic reactions even to nonrelated drugs. (51)
(51.) Smith J, Johnson J, Cluff L. Studies on the epidemiology of adverse drug reactions: II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998-1002.
FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including Han Chinese, Filipinos, Malaysians, South Asian Indians, and Thais. Until the FDA evaluation is completed, healthcare providers who are considering the use of phenytoin or fosphenytoin should be aware of the risks and benefits described in the current prescribing information for this drug. Healthcare providers should consider avoiding phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502. A summary of the data currently being analyzed by FDA, and information for patients and healthcare professionals to consider, can be found in the links provided in the MedWatch safety alert.
Read the MedWatch safety summary, including links to the Information for Healthcare Professionals and FDA Drug Information pages, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Phenytoin
FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including Han Chinese, Filipinos, Malaysians, South Asian Indians, and Thais. Until the FDA evaluation is completed, healthcare providers who are considering the use of phenytoin or fosphenytoin should be aware of the risks and benefits described in the current prescribing information for this drug. Healthcare providers should consider avoiding phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502. A summary of the data currently being analyzed by FDA, and information for patients and healthcare professionals to consider, can be found in the links provided in the MedWatch safety alert.
Read the MedWatch safety summary, including links to the Information for Healthcare Professionals and FDA Drug Information pages, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Phenytoin
FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including Han Chinese, Filipinos, Malaysians, South Asian Indians, and Thais. Until the FDA evaluation is completed, healthcare providers who are considering the use of phenytoin or fosphenytoin should be aware of the risks and benefits described in the current prescribing information for this drug. Healthcare providers should consider avoiding phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502. A summary of the data currently being analyzed by FDA, and information for patients and healthcare professionals to consider, can be found in the links provided in the MedWatch safety alert.
Read the MedWatch safety summary, including links to the Information for Healthcare Professionals and FDA Drug Information pages, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Phenytoin
FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including Han Chinese, Filipinos, Malaysians, South Asian Indians, and Thais. Until the FDA evaluation is completed, healthcare providers who are considering the use of phenytoin or fosphenytoin should be aware of the risks and benefits described in the current prescribing information for this drug. Healthcare providers should consider avoiding phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502. A summary of the data currently being analyzed by FDA, and information for patients and healthcare professionals to consider, can be found in the links provided in the MedWatch safety alert.
Read the MedWatch safety summary, including links to the Information for Healthcare Professionals and FDA Drug Information pages, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Phenytoin
